Heron Therapeutics (HRTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Heron Therapeutics (HRTX)
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Key Insights
Critical company metrics and information
Share Price
$1.77Market Cap
$269.21 MillionTotal Outstanding Shares
152.10 Million SharesTotal Employees
126Dividend
No dividendIPO Date
August 27, 1987SIC Description
Pharmaceutical PreparationsHomepage
https://www.herontx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $716,000.00 |
Net Cash Flow From Investing Activities, Continuing | $-1.54 Million |
Net Cash Flow | $-9.12 Million |
Net Cash Flow From Operating Activities, Continuing | $-8.29 Million |
Net Cash Flow From Investing Activities | $-1.54 Million |
Net Cash Flow From Operating Activities | $-8.29 Million |
Net Cash Flow From Financing Activities, Continuing | $716,000.00 |
Net Cash Flow, Continuing | $-9.12 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Income/Loss | $-25.92 Million |
Other Operating Expenses | $87.28 Million |
Net Income/Loss Attributable To Parent | $-27.97 Million |
Diluted Average Shares | $156.60 Million |
Research and Development | $38.07 Million |
Income/Loss From Continuing Operations After Tax | $-27.97 Million |
Diluted Earnings Per Share | $-0.16 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Earnings Per Share | $-0.16 |
Gross Profit | $99.43 Million |
Income/Loss From Continuing Operations Before Tax | $12.38 Million |
Revenues | $137.74 Million |
Benefits Costs and Expenses | $125.35 Million |
Cost Of Revenue | $38.30 Million |
Costs And Expenses | $125.35 Million |
Net Income/Loss | $-27.97 Million |
Basic Average Shares | $156.60 Million |
Operating Expenses | $125.35 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-27.97 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Non-current Assets | $10.18 Million |
Cash | $70.90 Million |
Liabilities And Equity | $220.78 Million |
Current Assets | $195.19 Million |
Accounts Payable | $10.19 Million |
Inventory | $45.95 Million |
Equity | $-40.01 Million |
Current Liabilities | $85.54 Million |
Liabilities | $260.78 Million |
Assets | $220.78 Million |
Noncurrent Liabilities | $175.24 Million |
Other Current Assets | $78.34 Million |
Equity Attributable To Parent | $-40.01 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Fixed Assets | $15.41 Million |
Noncurrent Assets | $25.59 Million |
Wages | $8.53 Million |
Other Current Liabilities | $66.83 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.